Feb 15, 2011 - 1:57 am
Here are good news from the European Urology published online 25 January 2011. This is from the world’s leading publisher of science and health information, Elsevier, based in Amsterdam, probably the most recognized reliable source of medical information in the world.
The news relate to a study named “The Use of 5α-Reductase Inhibitors (5-ARI) for the Prevention and Treatment of Prostate Cancer”.It was done in 389 patients on Active Surveillance (Watchful Waiting), on a long period of 15 years (1995 to 2010). The patients were initially diagnosed with low-risk prostate cancer, meaning that they belong to the wider population of cases in recent years.
In the full text from European Association of Urology, they comment that since the PSA testing “revolution”, it is estimated that 1 in 6 men will develop prostate cancer, but it is believed that only1in34 will die from the cancer.
Because of that,
“….The National Comprehensive Cancer Network and the National Institute for Health and Clinical Excellence both suggest that active surveillance be considered a first-line treatment strategy in low-risk disease…”
In commenting about the 5-ARI study, the EAU says;
Here is the full text;
Indolent cancers will be gone forever.